Ranking results:

Past rankings:

2020
Criterium:	Position:
Overall Score:	900-1000
Total Project Funding per Partner:	> 1000
Total Number of Projects:	600-700
2019
Criterium:	Position:
Overall Score:	200-300
Total Project Funding per Partner:	> 1000
Total Number of Projects:	100-200
2018
Criterium:	Position:
Overall Score:	800-900
Total Project Funding per Partner:	> 1000
Total Number of Projects:	400-500
Networking Rank (Reputation):	700-800
2017
Criterium:	Position:
Overall Score:	500-600
Total Project Funding per Partner:	500-600
Total Number of Projects:	500-600
Networking Rank (Reputation):	400-500
2016
Criterium:	Position:
Overall Score:	800-900
Networking Rank (Reputation):	700-800
2015
Criterium:	Position:
Overall Score:	> 1000
Networking Rank (Reputation):	> 1000

Ranking timeline:

Project Participation Performance(2015-01-01 - 2024-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 75
As coordinator: 1
As participant: 74
Sole participant: 0
Coordinator / Participant Ratio: 0.01^*

^*Ratio includes only projects with > 2 partners

Summary:

	Total project funding [€]:			Projects [No]:
Year:	coordinator^*	participant^*	per partner	as coordinator	as participant
2023	0	2.660.962	262.620		1
2022	0	6.498.997	216.799		2
2021	0	175.910.104	2.296.409		12
2020	0	154.106.951	255.250		6
2019	0	227.020.318	681.640		21
2018	2.054.499	164.854.672	134.531	1	6
2017	0	100.465.984	1.270.035		12
2016	0	82.314.814	430.674		11
2015	0	11.045.925	501.120		3

^*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:	Projects [No]:
NOVARTIS PHARMA	27
PFIZER LIMITED	24
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD	23
ELI LILLY AND COMPANY LIMITED	19
F HOFFMANNLA ROCHE	19
BAYER	17
SANOFIAVENTIS	17
KATHOLIEKE UNIVERSITEIT LEUVEN	16
UCB BIOPHARMA	16
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E V	13
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE	13
TAKEDA PHARMACEUTICALS INTERNATIONAL	13
ASTRAZENECA	12
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM	12
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT	12
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN	12
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL	12
TAKEDA DEVELOPMENT CENTRE EUROPE	12
UNIVERSITY COLLEGE LONDON	12
CHARITE UNIVERSITAETSMEDIZIN BERLIN	11
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE	11
NOVO NORDISK	11
STICHTING VUMC	11
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG	10
KING'S COLLEGE LONDON	10
THE UNIVERSITY OF EDINBURGH	10
UPPSALA UNIVERSITET	10
ABBVIE INC	9
KAROLINSKA INSTITUTE	9
STICHTING LYGATURE	9
UNIVERSITAIR MEDISCH CENTRUM UTRECHT	9
ACADEMISCH ZIEKENHUIS GRONINGEN	8
H LUNDBECK AS	8
MEDIZINISCHE UNIVERSITAET WIEN	8
UNIVERSITY OF NEWCASTLE UPON TYNE	8
ALZHEIMER EUROPE	7
ASTELLAS PHARMA EUROPE BV	7
ASTRAZENECA AB	7
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE	7
COMMISSARIAT A L'ENERGIE ATOMIQUE	7
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER IRIS	7
INSTITUT DE RECHERCHES SERVIER	7
LEIDS UNIVERSITAIR MEDISCH CENTRUM	7
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE	7
STICHTING KATHOLIEKE UNIVERSITEIT	7
UNIVERSITY OF DUNDEE	7
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN	6
SERVICIO MADRILENO DE SALUD	6
THE UNIVERSITY OF LIVERPOOL	6
THE UNIVERSITY OF MANCHESTER	6
ACADEMISCH ZIEKENHUIS LEIDEN	5
EUROPEAN CANCER PATIENT COALITION	5
FORUM DES PATIENTS EUROPEENS	5
GOETEBORGS UNIVERSITET	5
MERCK SHARP & DOHME CORP	5
ORION OYJ	5
SANOFIAVENTIS RECHERCHE & DEVELOPPEMENT	5
TEVA PHARMACEUTICAL INDUSTRIES LIMITED	5
UNIVERSITA VITASALUTE SAN RAFFAELE	5
UNIVERSITE DE GENEVE	5
UNIVERSITEIT ANTWERPEN	5
UNIVERSITEIT MAASTRICHT	5
UNIVERSITY OF CAMBRIDGE	5
UNIVERSITY OF COPENHAGEN	5
UNIVERSITY OF GLASGOW	5
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS	4
BAYER AKTIENGESELLSCHAFT	4
BIOGEN IDEC LIMITED	4
CELGENE MANAGEMENT SARL	4
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS	4
DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV	4
ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS	4
EUROPEAN MOLECULAR BIOLOGY LABORATORY	4
INSTITUT PASTEUR	4
KLINIKUM DER UNIVERSITAET ZU KOELN	4
LEIDEN UNIVERSITY	4
OSPEDALE PEDIATRICO BAMBINO GESU	4
RIJKSUNIVERSITEIT GRONINGEN	4
SANOFIAVENTIS DEUTSCHLAND	4
STICHTING BURO ECNP	4
THE HYVE BV	4
THE UNIVERSITY OF SHEFFIELD	4
TTOPSTART BV	4
UNIVERSIDAD POMPEU FABRA	4
UNIVERSITAETSKLINIKUM HEIDELBERG	4
UNIVERSITAT WIEN	4
UNIVERSITE D'AIX MARSEILLE	4
UNIVERSITE DE BORDEAUX	4
UNIVERSITY COLLEGE CORK NATIONAL UNIVERSITY OF IRELAND CORK	4
UNIVERSITY OF BIRMINGHAM	4
UNIVERSITY OF BOLOGNA	4
ABBVIE DEUTSCHLAND GMBH & CO KG	3
AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN	3
ARTTIC	3
BARCELONA SUPERCOMPUTING CENTER CENTRO NACIONAL DE SUPERCOMPUTACION	3
BAYER PHARMA	3
BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM	3
BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL	3
CENTRE DE RECHERCHE PUBLIC DE LA SANTE	3
COVANCE LABORATORIES	3

Constancy:

Total number of partners: 1698
Partner loyalty:
Frequent Partner: (> 2 projects): 886
Rare Partner: 812
Frequent / Rare Partner Ratio: 1.09

Project overview:

Start date	Project	acronym	role	funding	partners
2023-01-01	Doctoral network for microprocess engineering for electrosynthesis - new synthesis concepts for pharmaceutical/ fine chemical industry	MiEL	participant	2.660.962	14
2022-09-01	CREATING FRAMEWORK CONDITIONS FOR RESEARCH MANAGEMENT TO STRENGTHEN THE EUROPEAN RESEARCH AREA	RM ROADMAP	participant	1.499.997	8
2022-09-01	How to minimize the ecological footprint for functional electronics?	ECOTRON	participant	4.999.000	11
2021-11-01	European platform for neurodegenerative disorders	EPND	participant	9.680.000	29
2021-11-01	Preparing for RSV Immunisation and Surveillance in Europe	PROMISE	participant	3.744.375	22
2021-09-01	Allostery in Drug Discovery	ALLODD	participant	3.669.354	13
2021-09-01	BEhavioral and Adherence Model for improving quality, health outcomes and cost-Effectiveness of healthcaRe	BEAMER	participant	5.948.903	31
2021-06-01	Using real-world big data from eHealth, biobanks and national registries, integrated with clinical trial data to improve outcome of severe mental disorders	REALMENT	participant	6.000.000	15
2021-06-01	ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS	UNITE4TB	participant	92.500.000	32
2021-02-01	Central Repository for Digital Pathology	BIGPICTURE	participant	32.319.825	51
2021-01-01	Drug repurposing and discovery multidisciplinary training network	DRUGtrain	participant	2.394.817	8
2021-01-01	Advanced machine learning for Innovative Drug Discovery	AIDD	participant	3.926.573	17
2021-01-01	Boosting advanced doctoral training in innovative colon targeting drugs	COLOTAN	participant	3.533.108	10
2021-01-01	Accelerating Development and Improving Access to CAR and TCR-engineered T cell therapy	T2EVOLVE	participant	8.728.185	29
2021-01-01	A fully integrated, animal-free, end-to-end modelling approach to oral drug product development	InPharma	participant	3.464.964	11
2020-11-01	Accelerating Research & Development for Advanced Therapies	ARDAT	participant	11.773.000	34
2020-05-01	Process Analytical Technology Tools for Real-Time Physical and Chemical Characterization of Nanosuspensions	PAT4Nano	participant	5.092.409	10
2020-04-01	Swift COronavirus therapeutics REsponse	SCORE	participant	2.576.063	10
2020-04-01	Corona Accelerated R&D in Europe	CARE	participant	36.559.186	43
2020-01-01	PharmaLedger	PharmaLedger	participant	8.290.694	30
2020-01-01	EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS	ERA4TB	participant	89.815.600	33
2019-11-01	EU Patient- cEntric clinicAl tRial pLatform	EU-PEARL	participant	12.004.953	37
2019-11-01	Collaboration for Prevention and Treatment of MDR Bacterial Infections	COMBINE	participant	8.000.000	11
2019-11-01	Identifying Digital Endpoints to Assess FAtigue, Sleep and acTivities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory diseases	IDEA-FAST	participant	20.997.523	47
2019-10-01	A Centre of Excellence in Computational Biomedicine	CompBioMed2	participant	7.992.823	16
2019-10-01	Long Acting Medicines for Complex Therapeutics Needed Now	LongActNow	participant	1.292.901	3
2019-10-01	Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies	Immune-Image	participant	15.000.000	23
2019-09-01	Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions	3TR	participant	40.273.192	70
2019-09-01	Trials@Home: Center of Excellence – Remote Decentralised Clinical Trials	Trials@Home	participant	19.036.998	33
2019-06-01	MachinE Learning Ledger Orchestration for Drug DiscoverY	MELLODDY	participant	8.000.000	17
2019-05-01	Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs	RespiriNTM	participant	5.687.984	9
2019-05-01	Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors	RespiriTB	participant	6.840.000	9
2019-04-01	Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation	ConcePTION	participant	15.299.991	53
2019-04-01	The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use	VALUE-Dx	participant	6.799.100	26
2019-03-01	Efficiently Networking European Neurodegeneration Research	NEURONET	participant	1.199.125	10
2019-03-01	Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts	IMMUcan	participant	17.830.000	28
2019-03-01	EBiSC2 – A sustainable European Bank for induced pluripotent Stem Cells	EBiSC2	participant	4.599.648	18
2019-02-01	Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease	TransBioLine	participant	13.999.998	29
2019-01-01	Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics (IM2PACT) Into The Brain	IM2PACT	participant	9.000.000	27
2019-01-01	Remote Assessment of Disease and Relapse – Alzheimer’s Disease	RADAR-AD	participant	4.999.757	17
2019-01-01	Multiscale Analysis of Thermomechanical Behaviour of Granular Materials	MatheGram	participant	4.170.178	15
2019-01-01	FAIRplus	FAIRplus	participant	3.996.150	22
2018-12-01	European Screening Centre; Unique Library for Attractive Biology	ESCulab	participant	18.249.993	20
2018-11-01	Artificial Intelligence to transform Drug and Chemical safety testing	PATH-TOX	coordinator	2.054.499	3
2018-11-01	European Health Data and Evidence Network	EHDEN	participant	14.105.750	22
2018-06-01	Autism Innovative Medicine Studies – 2 – Trials	AIMS-2-TRIALS	participant	54.999.999	48
2018-05-01	Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope	PIONEER	participant	6.000.000	34
2018-05-01	conect4children (COllaborative Network for European Clinical Trials For Children)	c4c	participant	67.000.000	47
2018-03-01	Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes.	PARADIGM	participant	4.498.931	35
2017-10-01	European Quality In Preclinical Data	EQIPD	participant	4.495.523	30

overview shows latest 50 from 75 projects (2015-01-01 - 2024-12-31)
A full list of projects can be found here:

JANSSEN PHARMACEUTICA N.V. - BE